Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1634 1682 1683 3791
This examiner grants 46% of resolved cases
Jeanine Anne Goldberg in Art Unit 1634 of Tech Center 3700 has 826 resolved cases with an allowance rate of 45.8%. This moderate rate suggests a selective examination process where less than half of the applications reach a grant. The median days to allowance is 1271, indicating a prosecution timeline of about three and a half years. Practitioners should be prepared for a substantive and potentially lengthy engagement when working with the 45.8% baseline.
The interview lift is a very high 40.8%, which is a strong signal that interviews are extremely beneficial for this examiner. This lift can significantly improve the odds of success, making a grant much more likely for those who engage in direct communication. Practitioners should make interviews a central part of their strategy to navigate the 1271-day process and address the examiner's concerns. With 826 resolved cases, the data clearly shows that while the baseline is challenging, personal engagement is a highly effective way to secure a patent grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18463329 | COMPOSITIONS AND METHODS FOR MOLECULAR INVERSION PROBE ASSAYS | Non-Final OA | AFFYMETRIX, INC. |
| 18241411 | COMPOSITIONS AND METHODS FOR DETECTING GYNECOLOGICAL CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18690840 | Multimode Omics of Single Tissue Sample | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18551126 | BIOMARKERS FOR CONFORMATION OF RIDING TRAITS IN HORSES | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18363344 | METHODS, DEVICES, AND SYSTEMS FOR DETERMINING LOW GRADE GLIOMA (LGG) SUBTYPES IDENTIFIED THROUGH MACHINE LEARNING | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17819908 | USE OF GENOMIC SIGNATURES TO PREDICT RESPONSIVENESS OF PATIENTS WITH PROSTATE CANCER TO POST-OPERATIVE RADIATION THERAPY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18537540 | LINKED TRANSCRIPT SEQUENCING | Non-Final OA | Singular Genomics Systems, Inc. |
| 17399920 | CLASSIFICATION OF SUBTYPES OF KIDNEY TUMORS USING DNA METHYLATION | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 17928513 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | Non-Final OA | The Trustees of Princeton University |
| 18251528 | MULTIPLEX DETECTION OF BACTERIAL RESPIRATORY PATHOGENS | Final Rejection | Becton, Dickinson and Company |
| 18697422 | METHOD FOR ANALYZING STRUCTURAL VARIATION, PRIMER PAIR SET, AND METHOD FOR DESIGNING PRIMER PAIR SET | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 18008146 | TREATMENTS FOR A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 18261451 | METHODS TO PREDICT EFFECTS OF PERIOPERATIVE ADMINISTRATION OF METHADONE TO OPTIMIZE PAIN RELIEF AND AVOID ADVERSE EFFECTS | Non-Final OA | The Trustees of Indiana University |
| 18691704 | microRNA BIOMARKERS | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18699569 | CD274 REARRANGEMENTS AS PREDICTORS OF RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY | Non-Final OA | Foundation Medicine, Inc. |
| 18416592 | METHOD FOR PREPARING NUCLEIC ACID SAMPLE | Non-Final OA | KAO Corporation |
| 18015311 | METHOD FOR DETECTING SEVERITY OF ATOPIC DERMATITIS | Non-Final OA | KAO CORPORATION |
| 17922565 | METHOD FOR DETECTING ATOPIC DERMATITIS | Non-Final OA | KAO CORPORATION |
| 18391216 | PERIANAL SWAB PCR PANEL, METHODS, DEVICE, AND KITS | Non-Final OA | IDEXX Laboratories, Inc. |
| 18287849 | GENE POLYMORPHISM MARKERS FOR DETERMINING SKIN TURNOVER AND HYPER-KERATINIZATION AND USE THEREOF | Non-Final OA | LG HOUSEHOLD & HEALTH CARE LTD. |
| 17528699 | METHOD AND KIT FOR DETERMINING THE TISSUE OR CELL ORIGIN OF DNA | Non-Final OA | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. |
| 17741305 | METHYLATED CONTROL DNA | Non-Final OA | Exact Sciences Corporation |
| 17727128 | DETECTING ESOPHAGEAL DISORDERS | Non-Final OA | Exact Sciences Corporation |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | Non-Final OA | Georgetown University |
| 18425806 | RESPIRATORY BIOMARKER PANEL | Non-Final OA | Cepheid |
| 18490636 | COLLECTION KIT, METHOD, AND SYSTEM FOR THE DETECTION OF SEXUAL HEALTH CONDITIONS | Non-Final OA | Simple HealthKit, Inc. |
| 18251147 | A METHOD FOR SINGLE-CELL NASCENT RNA LABELING AND SEQUENCING | Final Rejection | SINGLERON (NANJING) BIOTECHNOLOGIES, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy